Advancements and Insights in Non–Muscle-Invasive Bladder Cancer: Emerging PD-1/PD-L1 Inhibitors : Episode 7
Opinion
Video
Phase 3 Trials of PD-1/PD-L1 Inhibitors in NMIBC
Key Takeaways
- CREST, POTOMAC, KEYNOTE, and ALBAN trials investigate PD-1/PD-L1 inhibitors for BCG-naive bladder cancer patients, focusing on efficacy and safety.
- Routes of administration vary, with some trials using intravenous delivery and others exploring intravesical administration to optimize therapeutic outcomes.
Panelists discuss the specific PD-1/PD-L1 inhibitors currently being investigated in phase 3 trials for BCG-naive patients with non–muscle-invasive bladder cancer (NMIBC), including CREST, POTOMAC, KEYNOTE, and ALBAN, detailing how routes of administration and durations of therapy vary among these agents and emphasizing the significance of differences in control arms within the trials.
EP: 1.Exploring NMIBC: Overview, Symptoms, Risk Factors and Staging
EP: 2.NMIBC Treatment Insights: Standard of Care, BCG Immune Response, and Patient Outcomes
EP: 3.Exploring PD-1/PD-L1 Pathways and Innovative Treatments for NMIBC
EP: 4.Innovations in NMIBC Treatment: The Synergy of BCG and PD-1/PD-L1 Inhibitors
EP: 5.Collaborative Strategies: Urologists and Oncologists Enhancing Outcomes for High-Risk NMIBC
EP: 6.Navigating PD-1/PD-L1 Agents: Influential Factors in Choosing the Right Therapy
Now Viewing
EP: 7.Phase 3 Trials of PD-1/PD-L1 Inhibitors in NMIBC
EP: 8.Examining the Effects of PD-1/PD-L1 Inhibitor Differences on Patient Outcomes: Adherence, BCG Maintenance, and Resource Management
Video content above is prompted by the following:
- Can you explain in detail which PD-1/PD-L1 inhibitors are being investigated in phase 3 trials for BCG-naive patients? [describe CREST, POTOMAC, KEYNOTE, ALBAN,] (PMID 38849286; DOI 10.1016/S0302-2838(24)01302-2)
- How do the routes of administration and durations of therapy differ among the agents/trials? Bedke 2023Steinberg 2024
Related Videos
Related Content
